Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Oxford BioMedica ( (GB:OXB) ) has shared an update.
Oxford Biomedica PLC announced that its issued share capital as of May 31, 2025, consists of 106,093,858 ordinary shares, with no shares held in treasury. This figure represents the total number of voting rights in the company, which shareholders can use to determine their notification requirements under FCA rules.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £740.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Spark’s Take on GB:OXB Stock
According to Spark, TipRanks’ AI Analyst, GB:OXB is a Neutral.
Oxford BioMedica’s moderate overall score reflects strong revenue growth and strategic expansion efforts, yet significant profitability and cash flow challenges remain. The positive outlook from the earnings call contributes to optimism, but valuation concerns and high leverage continue to pose risks. Technical indicators provide a stable outlook, balancing the company’s financial and operational challenges.
To see Spark’s full report on GB:OXB stock, click here.
More about Oxford BioMedica
OXB is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. With 30 years of experience, the company is a pioneer in viral vector development and manufacturing, collaborating with leading pharmaceutical and biotechnology companies. OXB offers a range of technologies for viral vector manufacturing and has facilities in the UK, France, and the US.
YTD Price Performance: -22.62%
Average Trading Volume: 260,990
Technical Sentiment Signal: Sell
Current Market Cap: £344.5M
Find detailed analytics on OXB stock on TipRanks’ Stock Analysis page.